CIK 0001802768
- Large accelerated filer
Royalty Pharma plc
Sign in to watch- Ticker
- RPRX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- Operating
- Phone
- +1 212-883-0200
- Business address
- 110 EAST 59TH STREET, NEW YORK, NY, 10022
- 4 Open-market sale EVP, Investments & CLO sold 192,221 shares at an average $33.70 ($6,478,587)
- 4 Open-market buy CEO, Chairman of the Board bought 150,000 shares at $32.25 ($4,837,440)
- 4 Open-market sale Director sold 1,750,000 shares at $32.82 ($57,435,000)
- 4 Open-market buy CEO, Chairman of the Board bought 230,000 shares at an average $33.38 ($7,676,824)
- 4 Derivatives Options or other derivatives
- 4 Conversion Director acquired 300,000 shares (conversion)
- 4 Grant or award Director acquired 1,049 shares (grant or award)
- 4 Grant or award Director acquired 1,049 shares (grant or award)
- 4 Open-market sale Director sold 139,950 shares at an average $36.31 ($5,081,111)
- 4 Open-market sale EVP, Investments & CLO sold 112,779 shares at an average $37.06 ($4,179,295)
- 4 Open-market sale EVP, Investments & CLO sold 25,000 shares at $37.27 ($931,658)
- 4 Open-market sale EVP, Research & Investments sold 23,333 shares at $37.30 ($870,239)
- 4 Conversion Director acquired 1,500,000 shares (conversion)
- 4 Conversion EVP, Research & Investments acquired 70,000 shares (conversion)
- 5 Insider Annual Insider Trading Report
- 4 Grant or award Director acquired 943 shares (grant or award)
- 4 Grant or award Director acquired 943 shares (grant or award)
- 4 Open-market sale Director sold 60,000 shares at an average $42.01 ($2,520,623)
- 4 Open-market sale Director sold 84,302 shares at $43.15 ($3,637,463)
- 4 Open-market sale Director sold 362,766 shares at an average $44.04 ($15,974,737)
Page 9 of 18 · 342 filings